A New Jersey public company has agreed to acquire Johns Hopkins spinout Haystack Oncology in a deal that could be worth up to $450 million, The Bsuiness Journals reports.
Quest Diagnostics will pay $300 million in cash at the closing of the acquisition and up to an additional $150 million if future performance milestones are met. The deal will close in the second quarter of this year. Read more.
